Avacopan Crisis, D-VRd Reversal, Mirvetuximab Access

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: NICE recommends mirvetuximab soravtansine via interim CDF, the D-VRd reversal and what segmented cost-effectiveness modelling now requires, and the avacopan cross-jurisdictional crisis with direct implications for how we treat pivotal trial integrity in submissions. Let's get into it.

MarcusFirst up — mirvetuximab soravtansine. NICE published final draft guidance on 4 June recommending Elahere, AbbVie's folate receptor alpha-targeting ADC, for FRα-positive platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer — adults who've had one to three prior lines. The access mechanism is interim CDF rather than routine commissioning from publication, with transition to routine commissioning 90 days post-final guidance.

SaraThe CDF placement is the tell here. NICE is signalling residual cost-effectiveness uncertainty — managed access as a bridge pending real-world outcomes data. For HEOR teams supporting this dossier or competitive programmes, that means the confirmatory data collection requirements aren't decorative. They will determine whether this goes to routine commissioning or gets stuck.

MarcusRight. And the biomarker stratification compounds the modelling complexity substantially. The eligible population in England is meaningfully smaller than the licensed population once you factor in FRα-positivity rates and companion diagnostic uptake assumptions. Your cost-effectiveness calculation lives or dies on those test-uptake inputs.

SaraI'd push back slightly on framing this as primarily a modelling challenge. The more strategically important signal is that NICE is operationally comfortable with folate receptor targeting as a mechanism. That has direct portfolio implications — if you have a competing ADC in gynaecological oncology approaching HTA entry, this decision establishes the comparator landscape and the biomarker-stratification expectation simultaneously. And with sacituzumab govitecan already in the CHMP's May 2026 session scope for expanded indications, the ADC competitive space in ovarian cancer is becoming increasingly crowded at both EMA and NICE levels at the same time.

MarcusWhich means the window for differentiated positioning is narrowing fast. If you're second or third into this space, your PICO is going to be defined against a biomarker-stratified reference case that already has CDF precedent. That's a harder room to walk into.

SaraAgreed. And the toxicity displacement argument — replacing weekly paclitaxel or pegylated liposomal doxorubicin, both carrying significant peripheral neuropathy, alopecia, and GI burden — is a quality of life narrative NICE found persuasive enough to move forward despite uncertainty. That's worth internalising for ADC submissions more broadly.

MarcusStory two — D-VRd. On 8 June, Johnson and Johnson confirmed NICE issued final draft guidance recommending the quadruplet regimen — daratumumab with bortezomib, lenalidomide and dexamethasone — for newly-diagnosed, transplant-ineligible multiple myeloma. This is a reversal from NICE's January 2026 rejection of the same regimen across both transplant-eligible and transplant-ineligible populations. The evidentiary basis is the Phase 3 CEPHEUS trial: MRD-negativity rate of 60.9% with D-VRd versus 39.4% with VRd alone at a median follow-up of 58.7 months.

SaraThe population split is the structural story here. NICE declined for transplant-eligible patients but reversed for transplant-ineligible. The almost certain explanation is the cost-effectiveness differential — no autologous SCT cost in the baseline pathway for transplant-ineligible patients changes the ICER materially. NICE separating populations within the same regimen based on cost-effectiveness by subgroup rather than clinical indication is now a pattern, not an anomaly. If you're still running monolithic population models in haematological malignancies, you're behind.

MarcusI'd go further on the MRD endpoint question. NICE accepting MRD-negativity rate as the evidentiary foundation for a positive recommendation — using it to justify longer-term survival projections — is a methodological position that wasn't this settled even two years ago. HEOR analysts need to routinely build MRD-to-survival extrapolation into their trial-to-decision timelines for haematological cancers now, not treat it as a special case.

SaraI'm not sure NICE has fully committed to that position though. Accepting it here under the weight of 58.7 months follow-up is not the same as establishing MRD as a validated surrogate for routine use. I'd be cautious about over-reading one decision as a green light for MRD-anchored submissions with shorter follow-up.

MarcusFair. But the precedent matters. And the budget impact context matters too — around 6,240 people in the UK are diagnosed with multiple myeloma each year. The first-line transplant-ineligible restriction narrows the eligible population, but first-line is first-line. Combined with NICE's broadened second-line belantamab mafodotin recommendation — expanded from those unsuitable for lenalidomide to a wider relapsed/refractory population — the entire myeloma treatment algorithm is being rewritten from a payer-coverage standpoint within a single guidance cycle.

SaraAnd that stacking effect is exactly why budget impact modelling for myeloma right now requires a full pathway view, not just the indication you're submitting for. If NICE is approving sequentially across lines, the NHS aggregate cost exposure is not captured in any single appraisal.

MarcusStory three — avacopan. This is the most consequential cross-jurisdictional pharmacovigilance case we've covered this year. In the week of 5 to 12 June, three things happened simultaneously: the MHRA formally opened a review of avacopan's benefits and risks, citing — and I'm quoting directly — 'questions about the integrity and reliability of the data from the pivotal clinical study underpinning the licence approval.' The New England Journal of Medicine opened an investigation into the ADVOCATE trial, the Phase 3 study published in its pages in 2021. And PRAC endorsed a Direct Healthcare Professional Communication for Tavneos to reinforce liver function monitoring and stopping rules for drug-induced liver injury and vanishing bile duct syndrome.

SaraAnd this sits on top of the FDA's 30 April Federal Register notice proposing to withdraw avacopan's approval — alleging data manipulation in the ADVOCATE trial endpoint adjudication and lack of substantial evidence of effectiveness. Public comment period runs through 29 June. Amgen declined voluntary withdrawal, citing at least 23 published real-world studies and nearly five years of clinical use.

MarcusThe HEOR angle here is one that I think is being underweighted in the commentary. Amgen's defence is essentially a real-world evidence argument — that post-market data validates the clinical effect regardless of what happened in the pivotal trial. That is a genuinely novel evidentiary claim in a withdrawal proceeding. If it has any traction, it changes how we think about the relationship between pivotal trial integrity and real-world supplemental evidence in regulatory decisions.

SaraI disagree with that framing. The FDA's allegation is data manipulation, not an underpowered study or a surrogate endpoint dispute. Real-world evidence cannot rehabilitate a manipulated randomised trial — those are structurally different evidentiary problems. If the ADVOCATE endpoint adjudication was compromised, 23 observational studies don't resolve that. They address a different question entirely.

MarcusThat's true as a matter of regulatory logic. But from an HEOR submission standpoint, the question that's now live for any team with a dossier referencing ADVOCATE as a data source — directly or as an evidence network node — is how to handle a pivotal trial that is simultaneously under MHRA review, NEJM investigation, and FDA withdrawal proceedings. You cannot simply footnote that away.

SaraAgreed on that. The dossier hygiene problem is real. And the PRAC DHPC on liver injury runs in parallel — that's the EMA managing the known safety signal independently of the integrity question. These are two different regulatory processes addressing two different failure modes, and they're happening at the same time. That's an unusual level of simultaneous regulatory stress on a single product.

MarcusStory four — valproate. On 8 to 11 June, PRAC concluded its review of valproate and paternal exposure. The finding: evidence on neurodevelopmental disorders in children born to men treated with valproate is 'inconsistent' and a causal role is uncertain. Despite that explicit uncertainty, the committee recommended maintaining existing precautionary measures put in place in 2024 — measures covering male patients during the three months before conception — and updating product information to reflect the most recent data.

SaraThe methodological precedent here is the part worth dwelling on. PRAC is not confirming a risk. It is formally acknowledging that the evidence cannot resolve the question, and deciding that precautionary measures remain proportionate to the degree of uncertainty. Under GVP Module IX signal management, that puts this in a specific category — a signal that cannot be confirmed or refuted after structured evaluation. The decision to maintain precaution under explicit evidential failure is a standard-setter with real implications for CNS and neurological submissions where long-latency developmental outcomes are in play.

MarcusThe review was anchored in study EUPAS34201 — a retrospective observational study commissioned in 2018 across registry databases in Denmark, Sweden, and Norway. Six years from commission to conclusion. That is the operational reality of registry-based pharmacovigilance. If you are designing a PASS for a neurological medicine with any developmental outcome endpoint, the timeline assumptions in your RMP need to reflect that, not some optimistic two-year registry turnaround.

SaraAnd the broader signal for HEOR teams designing post-authorisation safety studies is that registry-based approaches carry inherent limits — not just in speed but in their capacity to resolve questions about low-frequency, long-latency outcomes. If regulators are prepared to maintain precautions indefinitely when registry evidence is inconclusive, the evidentiary bar for reversing a precautionary position is functionally undefined. That is a risk horizon that needs to be in your evidence strategy from day one, not retrofitted after a PASS delivers inconclusive results.

MarcusTo close — three things stick from this episode. The CDF interim access model for mirvetuximab soravtansine means the managed-access bridge is doing real evidentiary work, and biomarker-stratified population assumptions will determine whether this reaches routine commissioning. The D-VRd reversal is a concrete demonstration that population-segmented cost-effectiveness modelling is no longer optional in haematology — and the MRD endpoint question remains genuinely open, whatever this decision suggests.

SaraAnd the avacopan case is the one to watch. MHRA review, NEJM investigation, PRAC DHPC, FDA withdrawal proceedings — four simultaneous processes, two different failure modes. Whether real-world evidence can carry any weight in a data integrity proceeding is a question with no clean answer yet. The valproate conclusion adds a different dimension — when regulators are willing to institutionalise precaution under explicit uncertainty, your evidence strategy has to account for outcomes that may never be resolvable.

MarcusThat's Episode 33. Back tomorrow on Access Brief. Show notes at outcomes-analytica.no.